Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 8348

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blood (2021) 138 (9): 773–784.

https://doi.org/10.1182/blood.2020010510

Published: 2021

Includes: Supplemental data

Journal Articles

AML onco-niche: villain or ally?

Marta Derecka

Blood (2021) 138 (7): 504–506.

https://doi.org/10.1182/blood.2021012299

Published: 2021

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

Blood (2021) 138 (7): 557–570.

https://doi.org/10.1182/blood.2020009845

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

How I treat chronic lymphocytic leukemia after venetoclax

Thomas E. Lew, Constantine S. Tam, John F. Seymour

Blood (2021) 138 (5): 361–369.

https://doi.org/10.1182/blood.2020008502

Published: 2021

Journal Articles

Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia

Caiying Zhu, Yu Lian, Chenchen Wang, Peng Wu, Xuan Li, Yan Gao, Sibin Fan, Lanlan Ai, Liwei Fang, Hong Pan, Tao Cheng, Jun Shi, Ping Zhu

Blood (2021) 138 (1): 23–33.

https://doi.org/10.1182/blood.2020008966

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Blood (2020) 136 (13): 1507–1519.

https://doi.org/10.1182/blood.2019003654

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat relapsed or refractory AML

Susan DeWolf, Martin S. Tallman

Blood (2020) 136 (9): 1023–1032.

https://doi.org/10.1182/blood.2019001982

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Blood (2020) 136 (4): 480–488.

https://doi.org/10.1182/blood.2020005674

Published: 2020

Includes: Supplemental data

Journal Articles

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Blood (2020) 136 (3): 353–361.

https://doi.org/10.1182/blood.2019004221

Published: 2020

Includes: Supplemental data

NARROW

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

AML onco-niche: villain or ally?

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

How I treat chronic lymphocytic leukemia after venetoclax

Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

DARTs point the way forward in AML

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

How I treat relapsed or refractory AML

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only